Analysen von James Gordon
| 01.11.18 | MorphoSys overweight | JP Morgan Chase & Co. | |
| 30.10.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 29.10.18 | GSK Neutral | JP Morgan Chase & Co. | |
| 08.10.18 | GSK Neutral | JP Morgan Chase & Co. | |
| 01.10.18 | MorphoSys overweight | JP Morgan Chase & Co. | |
| 25.09.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 25.09.18 | GSK Neutral | JP Morgan Chase & Co. | |
| 18.09.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
|
Werbung
|
|||
| 18.09.18 | GSK Neutral | JP Morgan Chase & Co. | |
| 07.08.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 03.08.18 | GSK Neutral | JP Morgan Chase & Co. | |
| 02.08.18 | MorphoSys overweight | JP Morgan Chase & Co. | |
| 26.07.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 23.07.18 | GSK Neutral | JP Morgan Chase & Co. | |
| 20.07.18 | GSK Neutral | JP Morgan Chase & Co. | |
| 20.07.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 19.07.18 | MorphoSys overweight | JP Morgan Chase & Co. | |
| 09.07.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 20.06.18 | GSK Neutral | JP Morgan Chase & Co. | |
| 06.06.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 31.05.18 | GSK Neutral | JP Morgan Chase & Co. | |
| 28.05.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 18.05.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 17.05.18 | MorphoSys overweight | JP Morgan Chase & Co. | |
| 15.05.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 24.04.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 13.04.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 14.03.18 | MorphoSys overweight | JP Morgan Chase & Co. | |
| 13.03.18 | MorphoSys overweight | JP Morgan Chase & Co. | |
| 27.02.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 12.02.18 | GSK Neutral | JP Morgan Chase & Co. | |
| 08.02.18 | GSK Neutral | JP Morgan Chase & Co. | |
| 06.02.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 05.02.18 | GSK Neutral | JP Morgan Chase & Co. | |
| 02.02.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 31.01.18 | GSK Neutral | JP Morgan Chase & Co. | |
| 29.01.18 | GSK Neutral | JP Morgan Chase & Co. | |
| 18.01.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 15.01.18 | MorphoSys overweight | JP Morgan Chase & Co. | |
| 29.12.17 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 13.12.17 | GSK Neutral | JP Morgan Chase & Co. | |
| 12.12.17 | MorphoSys overweight | JP Morgan Chase & Co. | |
| 30.11.17 | AstraZeneca Neutral | JP Morgan Chase & Co. | |
| 30.11.17 | GSK Neutral | JP Morgan Chase & Co. | |
| 08.11.17 | MorphoSys overweight | JP Morgan Chase & Co. | |
| 07.11.17 | MorphoSys overweight | JP Morgan Chase & Co. | |
| 03.11.17 | AstraZeneca Neutral | JP Morgan Chase & Co. | |
| 02.11.17 | MorphoSys overweight | JP Morgan Chase & Co. | |
| 01.11.17 | AstraZeneca Neutral | JP Morgan Chase & Co. | |
| 27.10.17 | GSK neutral | JP Morgan Chase & Co. | |